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Abstract
Background: High expression of the RNA-binding protein RBM3 has previously been found to be associated with
good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study
was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer.
Findings: Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign
prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely
expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial
neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression
was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p =
0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p=0.021). These associations remained significant in
multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or
absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-
0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p=0.009 for clinical progression).
Conclusion: Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a
prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3
for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in
larger studies.
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Findings
Background and hypothesis
Prostate cancer is the leading cause of cancer death in
men in economically developed countries [1] and there
was an estimated 328 000 cases in Europe in 2008 which
makes it the most common form of cancer in men [2].
For localized cancer, radical prostatectomy is the most
common treatment and it has shown a benefit in cancer
specific survival in comparison to watchful waiting [3].
Nevertheless, in some cases the cancer will recur with
detectable prostate specific antigen (PSA) concentrations
in blood, known as biochemical recurrence (BCR) [4].
Apart from PSA, no diagnostic or prognostic biomarkers
have yet been incorporated into clinical protocols for
management and risk stratification of prostate cancer
patients despite extensive research efforts [5,6]. Thus,
there is still a great need for new biomarkers to predict
the course of the disease and differentiate indolent from
life threatening cancer.
The RNA-binding motif protein 3, RBM3, is a glycine
rich protein with an RNA recognition motif (RRM) cap-
able of binding to both RNA and DNA and it is one of the
earliest proteins synthesized in response to cold shock
[7,8]. RBM3 is up-regulated in various types of human
malignancies [9-11] and the role of RBM3 as a putative
cancer biomarker was originally unravelled using an anti-
body-based discovery approach http://www.proteinatlas.
org[12-14]. Since then, RBM3 protein expression, in
* Correspondence: Liv.Jonsson@med.lu.se
1Department of Clinical Sciences, Pathology, Lund University, Skåne
University Hospital, 221 85 Lund, Sweden
Full list of author information is available at the end of the article
Jonsson et al. Diagnostic Pathology 2011, 6:91
http://www.diagnosticpathology.org/content/6/1/91
© 2011 Jonsson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.particular its nuclear localization, has been demonstrated
to be associated with a significantly improved survival in
several cancer forms, e.g. breast cancer [11], ovarian can-
cer [15], malignant melanoma [16] and colorectal cancer
(Hjelm et al, Proteomics Clinical Applications, in press).
In ovarian cancer, RBM3 has also been demonstrated to
be an independent factor of good prognosis at the gene
expression level [15] and in vitro data point towards a link
between RBM3 and cisplatin sensitivity in ovarian cancer
cells [15], possibly by regulating several cellular processes
involved in maintenance of DNA integrity [17].
In this study, we investigated the prognostic impact of
RBM3 expression in prostate cancer by immunohisto-
chemical (IHC) analysis of benign and malignant speci-
mens from 88 patients treated with radical prostatectomy.
Patients and methods
The patient cohort consists of 88 patients, between 48-74
years, treated with radical prostatectomy for localized
prostate cancer at Skåne University Hospital, Malmö,
from 1998 - 2003. Patient and tumour characteristics are
shown in Additional File 1. Written consent was obtained
from the patients and the local ethics committee at Lund
University approved the study. Histopathological, clinical
and follow-up data were obtained from the clinical- and
pathology records. Vital status and cause of death was
obtained from the Swedish Cause of Death Registry up
until December 2006. The mean follow up period was 58.5
months after which three patients had died and 85
patients were alive. BCR was defined as PSA > 0.2 ng/ml
[18] with a confirmatory level and clinical progression
included BCR, death from prostate cancer and adjuvant
radiation therapy. During follow up, 14 (15.9%) patients
had BCR and 19 (21.6%) patients had clinical progression.
Five (5.7%) patients received adjuvant radiotherapy and
three (3.4%) patients received adjuvant hormonal therapy.
For tissue microarray (TMA) construction, areas repre-
senting cancer and normal prostate tissue were marked on
haematoxylin and eosin stained slides, whereby normal
tissue was sampled in a noncancerous zone away from the
tumour, in most cases the transition zone. Two 1.00 mm
cores from areas with invasive cancer and one 1.00 mm
core representing benign prostate tissue were sampled
from each case and mounted in a new recipient block
using a manual arraying device (MTA-1 Beecher Instru-
ments Inc., Sun Prairie, WI, USA). For immunohistochem-
ical analysis, 4 μm TMA-sections were automatically
pre-treated using the PT Link system and then stained in
an Autostainer Plus (DAKO; Glostrup, Copenhagen,
Denmark) with the mouse monoclonal anti-RBM3 anti-
body AAb030038; Atlas Antibodies AB, Stockholm,
Sweden, diluted 1:5000. The specificity of the antibody has
been validated previously [15]. RBM3 staining was evalu-
ated by two independent observers (LJ and KJ) who were
blinded to clinical and outcome data. The fraction of cells
expressing RBM3 in the nucleus (NF) were denoted a
score from 0 (0-1%), 1 (2-25%), 2 (26-50%), 3 (51-75%)
and 4 (> 75%) and the intensity (NI) was scored as 0
(negative), 1 (weak), 2 (moderate) and 3 (strong). A com-
bined nuclear score (NS) of NF × NI, was then con-
structed as previously described [15]. Cytoplasmic staining
intensity was graded as 0 (no staining), 1 (weak staining)
and 2 (strong staining).
Statistical analysis
Spearman’s rho and Chi-square tests were used for analy-
sis of the correlation between RBM3 expression and rele-
vant clinicopathological characteristics. Kaplan-Meier
analysis and log rank test were used to illustrate differ-
ences in BCR free time and progression free survival (PFS)
according to RBM3 expression. For survival analyses,
RBM3 expression (intensity × fraction) was dichotomized
into weak vs strong using classification and regression tree
analysis (CRT). Cox regression proportional hazards mod-
elling were used to estimate the impact of RBM3 expres-
sion on BCR (with RBM3 as a continuous variable) and
PFS (with RBM3 as a dichotomized variable) in both uni-
and multivariate analysis. All tests were two sided. A
p-value of 0.05 was considered significant. All statistical
analyses were performed using SPSS version 17 (SPSS Inc,
Chicago, IL).
Results
While absent or weakly expressed in benign prostatic
glands (Figure 1A), RBM3 was clearly up-regulated in pro-
static intraepithelial neoplasia (PIN) (Figure 1B) and in
invasive carcinoma RBM3 was expressed in various frac-
tions and intensities (Figure 1C-E) with 33 (37.5%) cases
lacking RBM3 expression (Figure 2). A progression
sequence with up-regulated RBM3 expression in PIN and
retained high RBM3 expression in the invasive component
is illustrated in Figure 3. There was no obvious heterogene-
ity in the staining pattern between duplicate tissue cores.
CRT analysis suggested an optimal cutoff point at NS >
2 to determine the impact of RBM3 expression on BCR
free survival and PFS. While there was no association
between RBM3 expression and conventional clinicopatho-
logical parameters (Additional File 2), Kaplan Meier analy-
sis demonstrated that high expression of RBM3 was
associated with a significantly prolonged time to BCR (p =
0.004) and clinical progression (p = 0.004) (Figure 4).
These associations were confirmed in Cox univariate ana-
lysis (HR 0.56, 95% CI: 0.34-0.93, p =0 . 0 2 4f o rB C Ra n d
HR 0.09, 95% CI: 0.01-0.71, p=0.021 for clinical progres-
sion) and remained significant in multivariate analysis,
adjusted for preoperative PSA level, Gleason score and
presence or absence of extracapsular extension, seminal
vesicle invasion and positive surgical margins (HR 0.41,
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0.01-0.50, p=0.009 for clinical progression) (Table 1).
These significant associations were retained in both uni-
variate and multivariate analysis also when the few
patients who received adjuvant radiotherapy or hormonal
therapy were excluded from the analysis (data not shown).
Cytoplasmic RBM3 expression was not prognostic (data
not shown).
Figure 1 RBM3 expression in normal prostatic epithelium, prostatic intraepithelial neoplasia and in prostate cancer.
Immunohistochemical images of RBM3 expression in (A) normal prostatic epithelium, (B) prostatic intraepithelial neoplasia and invasive prostate
cancer, ranging from (C) high, (D) moderate, (E) weak to (F) negative expression.
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Our results demonstrate that RBM3, while rarely
expressed in normal prostatic gland epithelium, is up-
regulated in PIN and invasive prostate cancer, and that
patients with tumours expressing high nuclear levels of
RMB3 have a significantly prolonged time to biochem-
ical recurrence and clinical progression, also after
adjustment for conventional prognostic factors. These
findings are in line with previous findings in breast can-
cer [11], ovarian cancer [15], malignant melanoma [16]
and colorectal cancer (Hjelm et al, Proteomics Clinical
Applications, in press). Thus, there are increasing evi-
dence for RBM3 being a biomarker of good prognosis in
multiple cancer forms. The mechanisms behind these
findings remain to be elucidated, an undertaking that
might be somewhat challenging as current in vitro data
point towards a proto-oncogenic role for RBM3 [8,9,19]
and, hence, do not readily seem to support the clinical
situation. However, the common hypothesis that onco-
gene activation is associated with an aggressive tumour
phenotype does not always hold true, as well exempli-
fied by the association between microsatellite instability
and good prognosis in colorectal cancer [20]. It is evi-
dent that RBM3, while sparsely expressed in normal tis-
sue, is up-regulated in most cancer forms and their pre-
invasive stages in vivo. In light of the recently proposed
association between RBM3 and DNA integrity in ovar-
ian cancer [17], it could be speculated that RBM3 might
play an important role in promoting early stages of
tumourigenesis by interfering with the anti-cancer
Figure 2 RBM3 staining distribution in prostate cancer.
Distribution of nuclear RBM3 staining in invasive prostate cancer,
denoted as nuclear score (fraction × intensity).
Figure 3 Example of RBM3 up-regulation in prostate cancer
progression. Immunohistochemical image depicting up-regulated
RBM3 expression in (A) PIN and (B) adjacent invasive component
with high RBM3 expression.
Figure 4 Prognostic value of RBM3 expression in prostate cancer.
Kaplan Meier curves visualizing the impact of RBM3 expression on (A)
biochemical recurrence free and (B) progression free survival.
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mechanisms [21-23]. On the other hand, once a tumour
has been established, an attenuated capability of DNA-
damage response caused by RBM3 over expression
might hinder the pressure for selection of more malig-
nant clones [21,22]. Further studies are warranted to
explore these associations.
In this study, we used a well-validated monoclonal anti-
body for detection of RBM3 expression [15,16]. Immuno-
histochemistry has several advantages compared to other
assays in that it can easily be incorporated into clinical
protocols and allows for assessment of the subcellular
localization of proteins, which might have important prog-
nostic implications. Our results indicate that immunohis-
tochemical assessment of RBM3 expression in formalin-
fixed paraffin embedded tumour samples could be a useful
tool for prognostication and treatment stratification of
prostate cancer patients. Since this was a small study these
findings should be further validated in larger studies, pre-
ferably tumours from prospective, clinical trials.
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